Healthcare Industry News: Bard
News Release - September 9, 2013
DFINE Hires Greg Barrett As New President and CEOFormer BARRX President and CEO Brings Extensive Operations and Commercial Experience to Fast Growing Spine Therapy Company
SAN JOSE, Calif.--(Healthcare Sales & Marketing Network)--DFINE, Inc., a fast growing market leader in the treatment of spinal diseases today announced the appointment of Greg Barrett as President and Chief Executive Officer. Mr. Barrett assumes those roles from Kevin Mosher whose 4 years of service helped establish DFINE’s strong foundation. Mr. Mosher is returning to the dental field as CEO of ClearChoice™ in Denver, Colorado.
Mr. Barrett brings more than 35 years of medical technology leadership experience to DFINE. Most recently, he was Chairman, President and CEO of BÂRRX Medical, where he guided the company’s $325M sale to Covidien in 2012. Before joining BÂRRX in 2004, Greg served as President and CEO of ACMI Corporation, Group Executive Vice President at Boston Scientific Corporation, and held positions as Vice President, Global Sales and Marketing at Orthofix Corporation and Baxter Healthcare. He also spent 13 years at C.R. Bard Corporation, where he was Vice President of Marketing in the Cardiosurgery Division. Greg sits on the Board of Monteris Medical, BaroSense, Inc. and Cutera, Inc. He holds a B.A. in Marketing from the University of Texas, Austin.
“After looking at a number of opportunities following Covidien’s acquisition of BÂRRX, DFINE stood out because of its innovative technology platform including the STAR™ Tumor Ablation System for the treatment of painful spinal tumors and the StabiliT System for vertebral compression fracture repair. Both products represent very innovative solutions for the hundreds of thousands of patients suffering from these debilitating diseases of the spine. Patients, physicians and the health care system will greatly benefit as we expand availability of these therapies.”
Josh Baltzell, a managing director at Split Rock Partners and board member at DFINE commented, “We’re thrilled Greg is leading a very committed team forward. His proven skills will help DFINE build on its strong commercial success while setting the stage for global expansion that can benefit hundreds of thousands of patients.”
About DFINE, Inc.
DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from vertebral pathologies through innovative, minimally invasive, targeted therapies. The company’s devices are built on a radiofrequency (RF) platform that currently covers two procedural applications: The treatment of vertebral compression fractures (VCFs) with the StabiliT® Vertebral Augmentation System, and the palliative treatment of painful metastatic vertebral body lesions with the STAR™ Tumor Ablation System. Both systems represent generational advancements in the minimally invasive treatment of vertebral pathologies.
DFINE is a privately held company based in San Jose, California. Stay connected with DFINE via Facebook or Twitter(@DFINEinc) or call 1.866.963.3463.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.